Disease burden of gastric cancer in Chinese population: a comparison between 1990 and 2017

GUO Jia; HE Yuan; WANG Xue-mei

doi:10.11847/zgggws1134352

Volume 38 Issue 5

May 2022

Turn off MathJax

Article Contents

Article Navigation > Chinese Journal of Public Health > 2022 > 38(5): 547-552

GUO Jia, HE Yuan, WANG Xue-mei, . Disease burden of gastric cancer in Chinese population: a comparison between 1990 and 2017[J]. Chinese Journal of Public Health, 2022, 38(5): 547-552. doi: 10.11847/zgggws1134352

Citation:

GUO Jia, HE Yuan, WANG Xue-mei, . Disease burden of gastric cancer in Chinese population: a comparison between 1990 and 2017[J]. Chinese Journal of Public Health, 2022, 38(5): 547-552. doi: 10.11847/zgggws1134352

Citation:

PDF( 524 KB)

Disease burden of gastric cancer in Chinese population: a comparison between 1990 and 2017

doi: 10.11847/zgggws1134352

1.
School of Public Health, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010110, China

Received Date: 2021-02-18
Available Online: 2022-04-29
Publish Date: 2022-05-20

Abstract

Abstract

Objective To compare the disease burden of gastric cancer among Chinese residents in 1990 and 2017 for providing references to decision making on gastric cancer prevention and health management. Methods Using the data of 1990 and 2017 from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, we analyzed the changes in years of life lost (YLL), years living with disability (YLD) and disability-adjusted life years (DALY) due to gastric cancer in Chinese population between 1990 and 2017. Results In contrast with those in 1990, higher gastric cancer-related YLL (7 648 000 person-years [PYs] vs. 7 340 000 PYs), YLD ( 167 000 PYs vs. 74 000 PYs), standardized YLD rate (8.5/100 000 vs. 8.4/100 000) and DALY (7 815 000 PYs vs. 7 415000 PYs) were observed in 2017 in Chinese population, with the increasing percentage of 4.2%, 125.7%, 1.2%, and 5.4%; but the standardized YLL rate declined from 779/100 000 to 383.2/100 000 and the standardized DALY rate declined from 787.3/100 000 to 391.7/100 000. There were gender, age, and region differences in the changes between 1990 and 2017 for disease burden due to gastric cancer in the population; in the males, the YLD increased by 152.1%, higher than 76.9% in the females; while the standardized YLL and DALY rate decreased by 46.4% and 45.8% in the males, both lower than in female population (58.5% and 58.0%); the YLL, standardized YLD rate, and DALY of the males increased by 13.7%, 11.6%, and 15.1% but those of the females decreased by 12.7%, 19.0%, and 11.9%, respectively; the DALY decreased in people aged < 50 and 55 – 59 years but increased in the people of other age groups, with the highest increase of 133.5% in the people ≥ 80 years; the standardized DALY rate decreased among all age groups and the decrease percentage (75.7%) was the highest for the people aged 20 – 24 years; the highest increase of DALY (86.2%) was observed in the population of Shaanxi province whereas the greatest decrease of DALY (25.1%) was in the population of Tibet Autonomous Region; the standardized DALY rate decreased in all 33 provincial-level administrative divisions, with the greatest decrease (66.7%) in Beijing and the least decrease (14.7%) in Shaanxi province. Conclusion The disease burden of gastric cancer in Chinese population decreased in 2017 compared to that in 1990 but the decrease differed by gender and region and the disease burden is still at a relatively high level.
- stomach cancer,
- disease burden,
- comparison,
- Chinese residents

FullText(HTML)

References(33)

References

[1]	The International Agency for Research on Cancer. Latest global cancer data: cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020[EB/OL]. (2020 – 12 – 15) [2020 – 12 – 25].https://www.iarc.fr/faq/latest-global-cancer-data-2020-qa/.
[2]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality world-wide for 36 cancers in 185 countries[J]. CA:A Cancer Journal for Clinicians, 2018, 68(6): 394 – 424. doi: 10.3322/caac.21492
[3]	中国疾病预防控制中心慢性非传染性疾病预防控制中心, 国家卫生健康委统计信息中心. 中国死因监测数据集 – 2018[M]. 北京: 中国科学技术出版社, 2019.
[4]	Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980 – 2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. The Lancet, 2018, 392(10159): 1736 – 1788. doi: 10.1016/S0140-6736(18)32203-7
[5]	James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990 – 2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. The Lancet, 2018, 392(10159): 1789 – 1858. doi: 10.1016/S0140-6736(18)32279-7
[6]	Kyu HH, Abate D, Abate KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 – 2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. The Lancet, 2018, 392(10159): 1859 – 1922. doi: 10.1016/S0140-6736(18)32335-3
[7]	Kupka K. International Classification of Diseases: Ninth Revi-sion[J]. WHO Chronicle, 1978, 32(6): 219 – 225.
[8]	董景五. 疾病和有关健康问题的国际统计分类: 第十次修订本[M]. 2版. 北京: 人民卫生出版社, 2008.
[9]	Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study[J]. JAMA Oncology, 2018, 4(11): 1553 – 1568. doi: 10.1001/jamaoncol.2018.2706
[10]	Etemadi A, Safiri S, Sepanlou SG, et al. The global, regional, and national burden of stomach cancer in 195 countries, 1990 – 2017: a systematic analysis for the Global Burden of Disease study 2017[J]. The Lancet Gastroenterology and Hepatology, 2020, 5(1): 42 – 54. doi: 10.1016/S2468-1253(19)30328-0
[11]	Nagy P, Johansson S, Molloy-Bland M. Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA[J]. Gut Pathogens, 2016, 8(1): 8. doi: 10.1186/s13099-016-0091-7
[12]	Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection[J]. Alimentary Pharmacology and Therapeutics, 2018, 47(7): 868 – 876. doi: 10.1111/apt.14561
[13]	Lee YC, Chiang TH, Chou CK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis[J]. Gastroenterology, 2016, 150(5): 1113 – 1124. doi: 10.1053/j.gastro.2016.01.028
[14]	Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials[J]. BMJ, 2014, 348: g3174. doi: 10.1136/bmj.g3174
[15]	IARC Helicobacter pylori Working Group. Helicobacter pylori eradication as a strategy for preventing gastric cancer[R]. Lyon: International Agency for Research on Cancer (IARC Working Group Reports, No. 8), 2014.
[16]	Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis[J]. Gut, 2015, 64(9): 1353 – 1367. doi: 10.1136/gutjnl-2015-309252
[17]	Fallone CA, Chiba N, Van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults[J]. Gastroenterology, 2016, 151(1): 51 – 69.e14. doi: 10.1053/j.gastro.2016.04.006
[18]	Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Con-sensus Report[J]. Gut, 2017, 66(1): 6 – 30. doi: 10.1136/gutjnl-2016-312288
[19]	曾妙, 杨三三, 李雪诺, 等. 幽门螺旋杆菌的检测方法研究现状[J]. 海南医学, 2020, 31(6): 784 – 788. doi: 10.3969/j.issn.1003-6350.2020.06.031
[20]	王熙苑, 霍丽娟. 幽门螺杆菌感染的治疗新进展[J]. 国际消化病杂志, 2020, 40(4): 243 – 245. doi: 10.3969/j.issn.1673-534X.2020.04.008
[21]	王雯雯, 刘文斌, 曹广文. 胃癌发病性别差异的相关危险因素[J]. 上海预防医学, 2017, 29(4): 257 – 260, 284.
[22]	中华人民共和国中央人民政府. 国务院新闻办就《中国居民营养与慢性病状况报告（2020年）》有关情况举行发布会[EB/OL]. [2021– 12– 25]. http://www.gov.cn/xinwen/2020-12/24/content_5572983.htm.
[23]	孙晓东, 黄育北, 王波, 等. 中国人群吸烟与胃癌发病关系的Meta分析[J]. 中国慢性病预防与控制, 2009, 17(3): 247 – 251.
[24]	Li YT, Eshak ES, Shirai K, et al. Alcohol consumption and risk of gastric cancer: the Japan collaborative cohort study[J]. Journal of Epidemiology, 2021, 31(1): 30 – 36. doi: 10.2188/jea.JE20190304
[25]	国家统计局. 中国统计年鉴 (2015) [M]. 北京: 中国统计出版社, 2016.
[26]	常敏, 张久聪, 周琴, 等. 胃癌流行病学研究进展[J]. 胃肠病学和肝病学杂志, 2017, 26(9): 966 – 969. doi: 10.3969/j.issn.1006-5709.2017.09.002
[27]	Kamineni A, Williams MA, Schwartz SM, et al. The incidence of gastric carcinoma in Asian migrants to the United States and their descendants[J]. Cancer Causes and Control, 1999, 10(1): 77 – 83. doi: 10.1023/A:1008849014992
[28]	D′Elia L, Rossi G, Ippolito R, et al. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies[J]. Clinical Nutrition, 2012, 31(4): 489 – 498. doi: 10.1016/j.clnu.2012.01.003
[29]	GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990 – 2017: a systematic analysis for the Global Burden of Disease study 2017[J]. Lancet Gastroenterol Hepatol. 2020: 5(1): 42 – 54.
[30]	World Health Organization. Guideline: Sodium intake for adults and children[M]. Geneva: World Health Organization, 2012.
[31]	张继国, 王志宏, 杜文雯, 等. 2015年中国15个省份成年居民膳食钠的摄入状况[J]. 中华预防医学杂志, 2019, 53(5): 455 – 458. doi: 10.3760/cma.j.issn.0253-9624.2019.05.004
[32]	中国疾病预防控制中心, 中国疾病预防控制中心慢性非传染性疾病预防控制中心. 中国慢性病及其危险因素监测报告2013[M]. 北京: 军事医学出版社, 2016.
[33]	Wild CP, Weiderpass E, Stewart BW. World cancer report: cancer research for cancer prevention[R]. Lyon: International Agency for Research on Cancer, 2020.